Results 111 to 120 of about 601,308 (135)

Symptomatic Vitreomacular Adhesion.

Retina, 2013
Symptomatic vitreomacular adhesion describes symptomatic loss of visual function as a result of vitreous traction at the macula.Literature review.Symptomatic vitreomacular adhesion can occur in isolation as vitreomacular traction, which may lead to the development of a macular hole, or it may occur alongside epiretinal membrane.
Elena Nicod, Timothy Jackson, Panos Kanavos   +2 more
exaly   +5 more sources

Initial Outcomes Following Intravitreal Ocriplasmin for Treatment of Symptomatic Vitreomacular Adhesion

Ophthalmic Surgery Lasers and Imaging Retina, 2013
BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center. PATIENTS AND METHODS:
William E Smiddy, Stephen Schwartz, Audina M Berrocal   +2 more
exaly   +4 more sources

Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial

Ophthalmology, 2016
The Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial was designed to evaluate the long-term efficacy and safety profile of ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA)/vitreomacular traction, including full-thickness macular hole (FTMH).Phase 3b, randomized, sham ...
Pravin U Dugel, Michael Tolentino
exaly   +5 more sources

Early Evolution of the Vitreomacular Interface and Clinical Efficacy After Ocriplasmin Injection for Symptomatic Vitreomacular Adhesion

Ophthalmic Surgery Lasers and Imaging Retina, 2015
BACKGROUND AND OBJECTIVE: To determine early evolution of the vitreomacular interface and clinical efficacy and safety profile after ocriplasmin treatment. PATIENTS AND METHODS: Retrospective, multicenter, observational case series.
Elias Reichel, Michael SInger, Nadia K Waheed   +2 more
exaly   +4 more sources

Enzymatic Vitreolysis With Ocriplasmin for Vitreomacular Traction and Macular Holes [PDF]

New England Journal of Medicine, 2012
Vitreomacular adhesion can lead to pathologic traction and macular hole. The standard treatment for severe, symptomatic vitreomacular adhesion is vitrectomy.
Peter Stalmans, Julia Haller, Anselm Kampik   +2 more
exaly   +3 more sources

Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study

Ophthalmology Retina, 2019
To evaluate clinical outcomes and safety up to 12 months after ocriplasmin injection for the treatment of patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT) in a real-world setting.The Phase IV Ocriplasmin Research to Better Inform Treatment (ORBIT) trial (NCT02079883) was a Phase IV multicenter, prospective ...
Peter K Kaiser, Petra Kozma, Brian C Joondeph   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Ocriplasmin: A Review of Its Use in Patients With Symptomatic Vitreomacular Adhesion

Drugs, 2013
Ocriplasmin (JETREA(®)) is a recombinant human serine protease plasmin with proteolytic activity against the protein components (e.g. laminin, fibronectin and collagen) of the vitreous and vitreoretinal interface, thereby facilitating vitreous liquefaction and separation of vitreous from the retina.
Yahiya Y Syed, Sohita Dhillon
exaly   +3 more sources

Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion/Traction [PDF]

US Ophthalmic Review, 2015
Ocriplasmin has recently been introduced as a new treatment option for patients with symptomatic vitreomacular adhesion/vitreomacular traction (VMA/VMT). Understanding its potential as well as its limitations is crucial as it becomes an additional tool in the management of these diseases.
exaly   +2 more sources

Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion

Ophthalmology Retina, 2017
To assess anatomic and visual outcomes of ocriplasmin use for symptomatic vitreomacular adhesion (VMA).Retrospective chart review.Macula Society members were surveyed online to collect data on ocriplasmin for symptomatic VMA. Clinical and optical coherence tomography data were collected using standardized data entry forms.There were 208 patients (208 ...
Rahul N Khurana, Michel Farah, Michael J Elman   +2 more
exaly   +4 more sources

Treatment Outcomes and Spectral-Domain Optical Coherence Tomography Findings of Eyes With Symptomatic Vitreomacular Adhesion Treated With Intravitreal Ocriplasmin

American Journal of Ophthalmology, 2015
To determine treatment outcomes of intravitreal ocriplasmin in symptomatic vitreomacular adhesion.Retrospective interventional case series.setting: Private practice. study population: Thirty-five eyes (35 subjects) with symptomatic vitreomacular adhesion. intervention/observation: Intravitreal ocriplasmin injection from February to November 2013.
Joseph Raevis, Michael M Lai
exaly   +3 more sources